Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration (FDA) clearance to proceed with Phase 2 clinical development of its lead candidate, Lucid-MS (Lucid-21-302), for the treatment of multiple sclerosis (MS). The approval of the Investigational New Drug (IND) application allows the company to initiate a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. Trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as soon as possible.
The significance of this milestone lies in Lucid-MS's novel mechanism of action. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination—the process by which the protective myelin sheath around nerve fibers is damaged. Specifically, the candidate targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical models have demonstrated that Lucid-MS can both prevent and reverse myelin breakdown, a crucial distinction that could address the underlying neurodegenerative component of MS, potentially slowing or halting disease progression.
The FDA clearance follows promising Phase 1 trials in healthy participants, where Lucid-MS demonstrated a favorable safety profile and was well tolerated. With more than $10 million in cash, digital assets, and liquid investments reported as of March 31, 2026, Quantum BioPharma appears financially positioned to advance the clinical program. The company's focus on neurodegenerative and metabolic disorders, as well as alcohol misuse, is underscored by its wholly owned subsidiary, Lucid Psycheceuticals Inc., which is spearheading the development of Lucid-MS.
Multiple sclerosis affects millions worldwide, and current treatments often fail to prevent long-term disability. If Lucid-MS proves effective in Phase 2, it could represent a paradigm shift in MS therapy, offering a neuroprotective approach that complements or surpasses existing immunomodulatory drugs. The outcome of this trial will be closely watched by the medical community and investors alike, as it could pave the way for a first-in-class treatment that directly targets the root cause of myelin damage. For more details on the announcement, visit the full press release. Further updates on Quantum BioPharma's news can be found in the company's newsroom.
